Bendamustine + rituximab (BR)
Checked 2026-09-09
Indolent lymphoma and mantle cell lymphoma first line; fit CLL without del(17p) where targeted agents are unavailable
One cycle
every 28 days × 6 · about 24 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Bendamustine Alkylating agent (nitrogen mustard-purine hybrid) | 90 mg/m² (70 mg/m² in CLL combinations) | IV | D1, 2 | |
Rituximab Monoclonal antibody (anti-CD20, chimeric) | 375 mg/m² | IV | D1 |
Cycles
6
28-day cycle
Emetogenicity
Moderate (30-90%)
G-CSF
Not routine
Notes
- Prolonged lymphopenia: PJP and herpes prophylaxis; avoid BR immediately before CAR-T collection.
Used in
Products
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
R-CHOP
Diffuse large B-cell lymphoma, first line (6 cycles; 3-4 with radiotherapy for limited stage)
every 21 days × 6
Venetoclax + obinutuzumab (fixed duration)
Untreated CLL, all fitness levels
every 28 days × 12
Fludarabine + cyclophosphamide lymphodepletion, then CD19 CAR-T
Relapsed or refractory large B-cell lymphoma (second line if refractory or relapse within 12 months), B-ALL, follicular and mantle cell lymphoma
every 6 days